Entities / Company
Viking Therapeutics.
company in San Diego, United States
- Reports this week
- 14
- Active events
- 5
- Connections
- 62
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Well supported10 reports7 developments inside
-
Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Well supported16 reports1 development inside
-
Viking Therapeutics, Nasdaq, and Meta are involved in a market update regarding shared growth in growth sectors.Some support1 report
-
Viking Therapeutics' stock price dropped following a dilutive offering, with the company trading on Nasdaq.Some support1 report
-
Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.Some support1 report
Earlier this month
One to three months ago
-
Viking Therapeutics and NextCure, both clinical-stage biopharma companies, are being compared on affordability and analyst ratings.Some support1 report
-
Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.Some support1 report1 development inside
Gone quiet
No new reports in 90+ days-
Both Dyn and Viking Therapeutics are noted as competing firms within the clinical-stage biotech sector.Some support1 report
-
Viking Therapeutics is developing a drug for obesity, while analysts project global drug market growth to $150B by 2035.Some support2 reports
-
Viking Therapeutics' drug results were less favorable than Eli Lilly's, leading to speculation that Viking may seek a partnership or acquisition.Well supported3 reports1 development inside
-
Institutional investor Stanley Druckenmiller's firm must file Form 13F with the SEC regarding its new position in Viking Therapeutics, amidst market competition among weight loss drug companies.Some support1 report
-
Viking Therapeutics received positive results from its MAD trial, noting that the company benefits from Trump tariffs and onshoring policies.Some support2 reports
-
Viking Therapeutics and Incepta Pharmaceuticals are facing market scrutiny as their stock performance is compared against the S&P 500 and broader medical sector trends.Speculative1 report
-
Viking Therapeutics confirmed its global rights to the drug candidate VK2735 and secured manufacturing and supply partnerships with CordenPharma.Well supported8 reports
-
Viking Therapeutics' stock gained on July 18, 2025, exceeding the S&P 500's daily gain while the medical sector declined.Some support4 reports
-
Equinix provides AI infrastructure and analytics while Viking Therapeutics develops a breakthrough obesity drug.Speculative1 report
-
Goldman Sachs amassed bullish positions on Viking Therapeutics.Speculative1 report
-
GSK and Viking Therapeutics are seeking updates on potential collaboration prospects for drugs targeting NASH and X-ALD.Some support1 report
-
FMR LLC is the largest shareholder of Viking Therapeutics.Some support1 report
-
Viking Therapeutics completed enrollment in its Phase 2 trial and initiated the VANQUISH Phase 3 registration program for its drug VK2735.Some support2 reports
-
Brian Lian was appointed as the chief executive officer of Viking Therapeutics on July 24, 2025.Some support1 report
-
Pfizer exited its own GLP-1 program.Some support1 report
-
Zacks Rank categorizes stocks into five groups, information released on August 4, 2025, involving Viking Therapeutics.Some support1 report
-
Viking Therapeutics faced high dropout rates in clinical trials while investors showed preference for AI stocks for higher returns.Some support1 report
-
Viking Therapeutics participated in a conference hosted by Morgan Stanley on August 29, 2025.Some support2 reports
-
Viking Therapeutics is based in the United States.Well supported3 reports
-
Morgan Stanley issued buy ratings and price targets on Viking Therapeutics stock on May 27, 2026, with Truist Financial also involved.Some support6 reports
No events began in the chosen period. Widen it, or reset.
Around Viking Therapeutics this week
News at the entities that move Viking Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Viking Therapeutics
-
Novo Nordisk OperationalBridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Moves Viking Therapeutics
-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Viking Therapeutics
-
Truist Financial Mentioned togetherMarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.Moves Viking Therapeutics
-
Pfizer OperationalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Viking Therapeutics
-
Nasdaq Shared contextApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Viking Therapeutics
Connections
The 15 strongest of 62, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Eli Lilly and Company Operational
Viking Therapeutics and Eli Lilly are direct competitors in the high-stakes market for GLP-1/GIP agonist drugs targeting obesity and weight management.
-
Novo Nordisk Operational
Viking Therapeutics and Novo Nordisk are direct competitors in the global weight loss and obesity drug market, specifically targeting GLP-1/GIP agonist mechanisms.
-
FDA Structural
FDA provides necessary regulatory oversight and market access pathway for Viking Therapeutics' drug candidates.
-
Pfizer Operational
The companies are active competitors in the pharmaceutical market, with Pfizer's market shifts creating strategic interest in Viking Therapeutics.
-
Truist Financial Mentioned together
Truist Financial provides financial analysis, including buy ratings and price targets, on Viking Therapeutics' stock.
-
AbbVie Operational
AbbVie and Viking Therapeutics are identified as competitors and participants in biotech M&A speculation.
-
Dyn Operational
The firms actively compete within the clinical-stage biotech sector.
-
Nasdaq Shared context
Viking Therapeutics is a company listed and traded on the Nasdaq exchange.
Show all 15 connections
-
Cantor Fitzgerald Mentioned together
The relationship is defined by market research, specifically the issuance of a high price target for Viking Therapeutics by an analyst.
-
Morgan Stanley Mentioned together
Morgan Stanley provides market analysis, price targets, and conference coverage relevant to Viking Therapeutics' obesity drug pipeline.
-
Nvidia Mentioned together
The entities are mentioned together in a comparative context, specifically comparing Viking Therapeutics to a chipmaker.
-
San Diego Shared context
Viking Therapeutics maintains its corporate headquarters in San Diego, California.
-
NOVO Operational
The evidence indicates that NOVO and Viking Therapeutics are engaged in competition within the obesity market.
-
Fisher Investments Mentioned together
The relationship is based on a single, generic market observation regarding dilutive offerings and stock price drops.
-
S&P Global Market Intelligence Mentioned together
Both S&P Global Market Intelligence and Viking Therapeutics were observed in articles tracking stock movements on the same date.
History
Events by the month they beganSeptember 2026
4 events- Viking Therapeutics, Nasdaq, and Meta are involved in a market update regarding shared growth in growth sectors.
- Viking Therapeutics' stock price dropped following a dilutive offering, with the company trading on Nasdaq.
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
- Analyst provides a high price target for Viking Therapeutics stock.
August 2026
1 eventJune 2026
23 events- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.
- Both Dyn and Viking Therapeutics are noted as competing firms within the clinical-stage biotech sector.
- Viking Therapeutics is developing a drug for obesity, while analysts project global drug market growth to $150B by 2035.
- Viking Therapeutics' drug results were less favorable than Eli Lilly's, leading to speculation that Viking may seek a partnership or acquisition.
- Institutional investor Stanley Druckenmiller's firm must file Form 13F with the SEC regarding its new position in Viking Therapeutics, amidst market competition among weight loss drug companies.
- Viking Therapeutics received positive results from its MAD trial, noting that the company benefits from Trump tariffs and onshoring policies.
- Viking Therapeutics and Incepta Pharmaceuticals are facing market scrutiny as their stock performance is compared against the S&P 500 and broader medical sector trends.
- Viking Therapeutics confirmed its global rights to the drug candidate VK2735 and secured manufacturing and supply partnerships with CordenPharma.
- Viking Therapeutics' stock gained on July 18, 2025, exceeding the S&P 500's daily gain while the medical sector declined.
- Equinix provides AI infrastructure and analytics while Viking Therapeutics develops a breakthrough obesity drug.
- Goldman Sachs amassed bullish positions on Viking Therapeutics.
- GSK and Viking Therapeutics are seeking updates on potential collaboration prospects for drugs targeting NASH and X-ALD.
- FMR LLC is the largest shareholder of Viking Therapeutics.
- Viking Therapeutics completed enrollment in its Phase 2 trial and initiated the VANQUISH Phase 3 registration program for its drug VK2735.
- Brian Lian was appointed as the chief executive officer of Viking Therapeutics on July 24, 2025.
- Pfizer exited its own GLP-1 program.
- Zacks Rank categorizes stocks into five groups, information released on August 4, 2025, involving Viking Therapeutics.
- Viking Therapeutics faced high dropout rates in clinical trials while investors showed preference for AI stocks for higher returns.
- Viking Therapeutics participated in a conference hosted by Morgan Stanley on August 29, 2025.
- Viking Therapeutics is based in the United States.
- Morgan Stanley issued buy ratings and price targets on Viking Therapeutics stock on May 27, 2026, with Truist Financial also involved.